Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NeoSync

Explore full profile

NeoSync, Inc. is a clinical stage company That treatment of Major Depressive Disorder

Boston, United StatesFounded 2008Biotech & Life Sciences
Valuation $50–100M Last recorded · 2017
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for NeoSync and the history behind them.

About NeoSync

Founded in 2022 by Evis Drenova and Nick Zelei, NeoSync is a San Francisco-based company that has developed an open-source platform focused on data security and developer productivity. The company addresses the critical need for high-quality, safe data in non-production environments like development, testing, and CI/CD pipelines.

Evis Drenova, the CEO and co-founder, brings a diverse background in product management, enterprise sales, and consulting from his time at companies like Skyflow, IBM, and Oracle. His experience in data privacy at Skyflow and product leadership at TrueData directly informs NeoSync's mission. Nick Zelei, the CTO and co-founder, previously served as a Staff Software Engineer at Newfront, where he led the Platform Engineering team, providing him with deep insights into the infrastructure challenges that developers face. The idea for NeoSync originated from the co-founders' own frustrations with manually creating and managing inadequate test data.

NeoSync's core business revolves around a platform that empowers developers to create anonymized or synthetic data and synchronize it across various environments. This process allows companies, particularly those in regulated industries such as FinTech and HealthTech, to use production-like data for development and testing without exposing sensitive information. The platform operates on an open-source model, which allows enterprises to keep their sensitive data within their own infrastructure, addressing security and compliance concerns with regulations like GDPR and HIPAA. Revenue is generated through enterprise-grade features and a cloud-hosted version of the platform.

The platform's main service is to stream data from a source, such as a production database, transform it by anonymizing or generating synthetic data, and then sync it to one or multiple destinations. Key features include the ability to generate synthetic data from scratch, anonymize existing data using over 50 pre-built transformers, and subset data using SQL queries while maintaining referential integrity. It supports various structured and unstructured data sources, including Postgres, MySQL, MongoDB, and S3. For developers, NeoSync provides a CLI, SDKs, APIs, and a Terraform provider to integrate into their existing workflows. The platform also addresses the needs of AI/ML engineers by enabling them to detect and anonymize sensitive data in LLM prompts and generate high-quality data for training models.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2008
Headquarters
Boston, United States
Employees
4
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES D✓Equity / VC Aug 2017 $13M $52M Valiance Life Science Investments · Valiance Asset Management ↗
SERIES CEquity / VC Jan 2016 $12M $49M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

NeoSync website traffic

Latest recorded traffic for NeoSync is 160 monthly website visits. NeoSync's team grew 0% over the past year.

Latest monthly visits160 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Valiance Asset Management
  • Valiance Life Science Investments

Other known investors1 additional known investor

  • Invus Opportunities
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States50%
🇬🇧 United Kingdom50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NeoSync on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeoSync’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.